| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754276 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 10 Pages |
Abstract
Dasatinib could be an appropriate treatment option for imatinib-intolerant patients with CML, with cross-intolerance resulting in discontinuation in a few patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Hanna J. Khoury, Stuart L. Goldberg, Michael J. Mauro, Richard M. Stone, Michael W. Deininger, M. Brigid Bradley-Garelik, Hesham Mohamed, François Guilhot,